Literature DB >> 6372248

Malignant or accelerated hypertension.

N D Vaziri.   

Abstract

Malignant or accelarated hypertension is a life-threatening medical emergency that is a possible complication of practically any hypertensive disorder. If not promptly treated it can cause severe, rapidly progressive target-organ damage and death. While the histo-pathologic features of malignant hypertension are well recognized, the pathogenesis of the associated vascular lesions and the transition from a benign to a malignant phase are unclear. With adequate control of hypertension, progression to the accelarated or malignant phase can be prevented. Moreover, promptly and effectively reducing the blood pressure during the malignant phase can prevent, minimize or even reverse serious target organ injury. Malignant hypertension, therefore, is both preventable and treatable.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6372248      PMCID: PMC1021775     

Source DB:  PubMed          Journal:  West J Med        ISSN: 0093-0415


  73 in total

1.  Effects of antihypertensive treatment on the evolution of the renal lesions in malignant nephrosclerosis.

Authors:  L J McCORMACK; J E BELAND; R E SCHNECKLOTH; A C CORCORAN
Journal:  Am J Pathol       Date:  1958 Nov-Dec       Impact factor: 4.307

2.  Renal biopsies in hypertension.

Authors:  R H HEPTINSTALL
Journal:  Br Heart J       Date:  1954-04

3.  Necrotizing pulmonary arteritis occurring with congenital heart disease (Eisenmenger complex); report of case with necropsy.

Authors:  J W OLD; W O RUSSELL
Journal:  Am J Pathol       Date:  1950-09       Impact factor: 4.307

4.  Survival with scleroderma. II. A life-table analysis of clinical and demographic factors in 358 male U.S. veteran patients.

Authors:  T A Medsger; A T Masi
Journal:  J Chronic Dis       Date:  1973-10

5.  How an acute rise in arterial pressure damages arterioles. Electron microscopic changes during angiotensin infusion.

Authors:  F S Goldby; L J Beilin
Journal:  Cardiovasc Res       Date:  1972-09       Impact factor: 10.787

6.  Treatment of patients with microangiopathic haemolytic anaemia with heparin.

Authors:  M C Brain; L R Baker; J A McBride; M L Rubenberg; J V Dacie
Journal:  Br J Haematol       Date:  1968-12       Impact factor: 6.998

7.  The production and resolution of hypertensive vascular lesions in the rabbit.

Authors:  P R Allison; N Bleehan; W Brown; G W Pickering; A H Robb-Smith; R P Russell
Journal:  Clin Sci       Date:  1967-08       Impact factor: 6.124

8.  Association of accelerated (malignant) hypertension in a patient with primary aldosteronism.

Authors:  F Del Greco; R Dolkart; J Skom; H Method
Journal:  J Clin Endocrinol Metab       Date:  1966-08       Impact factor: 5.958

9.  Prazosin and hydrallazine in the treatment of hypertension.

Authors:  P Kincaid-Smith; A S Hua; J B Myers; I MacDonald; P Fang
Journal:  Clin Sci Mol Med Suppl       Date:  1976-12

10.  Renal tuberculosis presenting with accelerated hypertension.

Authors:  P J Oldershaw; R P Edmondson
Journal:  Tubercle       Date:  1978-09
View more
  2 in total

1.  Hypertensive emergency: case criteria, sociodemographic profile, and previous care of 100 cases.

Authors:  N M Bennett; S Shea
Journal:  Am J Public Health       Date:  1988-06       Impact factor: 9.308

Review 2.  Relative effectiveness of clinic and home blood pressure monitoring compared with ambulatory blood pressure monitoring in diagnosis of hypertension: systematic review.

Authors:  J Hodgkinson; J Mant; U Martin; B Guo; F D R Hobbs; J J Deeks; C Heneghan; N Roberts; R J McManus
Journal:  BMJ       Date:  2011-06-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.